Last reviewed · How we verify

BET Inhibitor — Competitive Intelligence Brief

BET Inhibitor (BET Inhibitor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BET inhibitor. Area: Oncology.

phase 2 BET inhibitor BET proteins Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BET Inhibitor (BET Inhibitor) — Bristol-Myers Squibb. BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BET Inhibitor TARGET BET Inhibitor Bristol-Myers Squibb phase 2 BET inhibitor BET proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BET inhibitor class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BET Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/bet-inhibitor. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: